Elisabetta Bonzano: Internal Mammary Lymphadenopathy in Patients Treated with Neoadjuvant Chemotherapy

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:

“Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial Annals of Surgical Oncology

With a median follow up of 3.72 years (range 0.4-10.2), there was no difference between IM+ versus IM- in
LRR (5.6% vs. 3.8%; p = 0.25),
DR (9.1% vs. 7.9%; p = 0.58),
or EFS (61.6% vs. 57.2%; p = 0.48).
This was true for patients with and without pCR.”